Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.
Inotiv, Inc. reports news as a contract research organization providing nonclinical and analytical drug discovery and development services, research models, and related products for pharmaceutical, chemical, medical device, and biomedical research customers. Its updates commonly address Discovery and Safety Assessment activity, Research Models and Services performance, quarterly and annual financial results, and business trends tied to discovery, preclinical, and translational research demand.
Company announcements also cover collaborations and technology additions such as human-relevant in vitro models, AI-assisted bioinformatics, and multi-omics analysis within Discovery & Translational Sciences. Other recurring items include conference-call schedules, operational business updates, cybersecurity incident notices, and corporate communications affecting Nasdaq-listed common stock.
Inotiv (NASDAQ:NOTV) has partnered with PhoenixBio Co., Ltd. to enhance research services at its U.S. labs using the proprietary PXB-mouse® model. This collaboration is set to advance translational research for hepatic diseases and gene therapies, leveraging Inotiv's expertise with liver-humanized models.
Kelly Long, Inotiv's Senior Director, emphasized the importance of this partnership in providing advanced evaluation methods for new therapies. The PXB-mouse® is widely used for drug metabolism and pharmacokinetics, indicating a robust demand for its applications.